4 assets in Toxic Dermatosis

Therapeutic assets addressing Toxic Dermatosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cetuximab Toxic Dermatosis	Sun Yat-sen University	P2	CCC (53)
Clindamycin Toxic Dermatosis	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Crisaborole Toxic Dermatosis	Sun Yat-sen University	P2	CCC (53)
Kenacort Toxic Dermatosis	Memorial Sloan Kettering Cancer Center	P2	CCC (53)